FIELD: biotechnology.
SUBSTANCE: present invention relates to an Fc variant containing a combination of substituting amino acids in a specific position EU in a wild-type Fc protein. Said Fc variant has altered binding affinity to FcRn.
EFFECT: variant Fc, obtained according to the present invention, can be used to produce an FcRn antagonist composition or can be used to produce a Fc variant containing a drug or molecule with an altered effector function.
15 cl, 7 dwg, 11 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS ASSOCIATED WITH ENGINEERED Fc-CONSTRUCTS | 2018 |
|
RU2816477C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE ERYTHROCYTE COUNT | 2020 |
|
RU2814047C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
